Literature DB >> 25240528

Glypican-4 is increased in human subjects with impaired glucose tolerance and decreased in patients with newly diagnosed type 2 diabetes.

Ke Li1, Xiaohui Xu, Wenjing Hu, Minyan Li, Mengliu Yang, Yaxu Wang, Yong Luo, Xianxiang Zhang, Hua Liu, Ling Li, Gangyi Yang.   

Abstract

CONTEXT: Glypican-4 (GPC-4) has been identified as a novel adipokine capable of enhancing insulin signaling. A significant association between circulating GPC-4 levels and nonalcoholic fatty liver disease and cardiometabolic risk factors has been found in women.
OBJECTIVE: The aim of the present study was to investigate the relationship between GPC-4 and insulin resistance in cross-sectional and interventional studies. PATIENTS AND
DESIGN: We measured circulating GPC-4 (determined with ELISA) in subjects with NGT, IGT, and nT2DM. Euglycemic-hyperinsulinemic clamps were performed in healthy and T2DM subjects. Real-time RT-PCR and Western blotting were used to assess mRNA and protein expression of GPC-4.
RESULTS: Circulating GPC-4 levels were significantly higher in IGT subjects and lower in nT2DM subjects compared to controls. Circulating GPC-4 was positively correlated with BMI, WHR, HOMA-IS, and FAT%, while it was inversely correlated with FBG and HbA1c. Excluding diabetic subjects, increasing GPC-4 levels were associated with HOMA-IR and M values. Significantly lower GPC-4 mRNA and protein levels were found in muscle and fat of nT2DM patients, compared to controls. GPC-4 levels were significantly increased upon an oral glucose intake. The secretion of GPC-4 exhibited a characteristic diurnal rhythm in humans, with a major rise occurring between afternoon and midnight.
CONCLUSIONS: Circulating GPC-4 is elevated in prediabetic subjects and is reduced in nT2DM patients. The elevated GPC-4 appears to be associated with insulin resistance and obesity in IGT subjects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25240528     DOI: 10.1007/s00592-014-0652-5

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  7 in total

1.  Evaluation of the association of serum glypican-4 with prevalent and future kidney function.

Authors:  Axel Muendlein; Eva Maria Brandtner; Andreas Leiherer; Kathrin Geiger; Christine Heinzle; Stella Gaenger; Peter Fraunberger; Dominik Haider; Christoph H Saely; Heinz Drexel
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

2.  Correlation of Glypican-4 Level with Basal Active Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes Mellitus.

Authors:  Sang Ah Lee; Gwanpyo Koh; Suk Ju Cho; So Yeon Yoo; Sang Ouk Chin
Journal:  Endocrinol Metab (Seoul)       Date:  2016-09

Review 3.  Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation.

Authors:  Ariane R Pessentheiner; G Michelle Ducasa; Philip L S M Gordts
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

4.  Circulating alarin concentrations are high in patients with type 2 diabetes and increased by glucagon-like peptide-1 receptor agonist treatment: An Consort-compliant study.

Authors:  Wenjing Hu; Xiaoyun Fan; Baoyong Zhou; Ling Li; Bo Tian; Xia Fang; Xiaohui Xu; Hua Liu; Gangyi Yang; Yongsheng Liu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

5.  Glypican-4 in pregnancy and its relation to glucose metabolism, insulin resistance and gestational diabetes mellitus status.

Authors:  Carola Deischinger; Jürgen Harreiter; Karoline Leitner; Luna Wattar; Sabina Baumgartner-Parzer; Alexandra Kautzky-Willer
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

6.  DOCK5 regulates energy balance and hepatic insulin sensitivity by targeting mTORC1 signaling.

Authors:  Yerui Lai; Anjiang Zhao; Minghong Tan; Mengliu Yang; Yao Lin; Shengbing Li; Jinlin Song; Hongting Zheng; Zhiming Zhu; Dongfang Liu; Chaohong Liu; Ling Li; Gangyi Yang
Journal:  EMBO Rep       Date:  2019-12-29       Impact factor: 8.807

7.  Endurance exercise training restores diabetes-induced alteration in circulating Glycosylphosphatidylinositol-specific phospholipase D levels in rats.

Authors:  Farzad Abdolmaleki; Ali Heidarianpour
Journal:  Diabetol Metab Syndr       Date:  2020-05-19       Impact factor: 3.320

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.